Pre-Test Treatment Strategies for the Management of Multiple Myeloma: Frontline Therapy and Beyond Pre-Test 1. _______________, a selective inhibitor of nuclear export, is being tested in combination with daratumumab, lenalidomide, and dexamethasone for front-line treatment of multiple myeloma (MM) in a phase 2 clinical trial. Belantamab mafodotin Carfilzomib Selinexor Teclistamab Unsure 2. Which of the following is true regarding combination regimens with selinexor in MM? Selinexor combinations do not increase the risk of polypharmacy Selinexor given prior to non-cellular anti-BCMA therapies decreases overall survival Selinexor is FDA-approved in combination with dexamethasone for newly diagnosed MM Selinexor is FDA-approved in combination with dexamethasone for R/R MM after 4 therapies Unsure 3. Which of the following is true regarding all-oral regimens for MM? Medication adherence correlates with treatment satisfaction Oral regimens are less effective than intravenous regimens Oral regimens have lower tolerability than intravenous regimens Patient compliance is highest with oral regimens Unsure 4. What is the recommended management strategy for gastrointestinal toxicities associated with selinexor? Administration of antibiotics Discontinuation of selinexor Increase in selinexor dosage Prophylactic treatment for nausea and vomiting Unsure 5. How confident are you in your ability to select and sequence therapies for patients with MM based on current clinical evidence? Very confident Confident Somewhat confident Not very confident Not at all confident
